Show simple item record

dc.contributor.authorElaskalani, O.
dc.contributor.authorKhan, I.
dc.contributor.authorMorici, M.
dc.contributor.authorMatthysen, C.
dc.contributor.authorSabale, M.
dc.contributor.authorMartins, R.
dc.contributor.authorVerdile, G.
dc.contributor.authorMetharom, Pat
dc.identifier.citationElaskalani, O. and Khan, I. and Morici, M. and Matthysen, C. and Sabale, M. and Martins, R. and Verdile, G. et al. 2017. Oligomeric and fibrillar amyloid beta 42 induce platelet aggregation partially through GPVI. Platelets: pp. 1-6.

© 2017 Taylor & Francis The effects of the Alzheimer’s disease (AD)-associated Amyloid-ß (Aß) peptides on platelet aggregation have been previously assessed, but most of these studies focused on Aß40 species. It also remains to be determined which distinct forms of Aß peptides exert differential effects on platelets. In AD, oligomeric Aß42 species is widely thought to be a major contributor to the disease pathogenesis. We, therefore, examine the ability of oligomeric and fibrillary Aß42 to affect platelet aggregation. We show that both forms of Aß42 induced significant platelet aggregation and that it is a novel ligand for the platelet receptor GPVI. Furthermore, a novel binding peptide that reduces the formation of soluble Aß42 oligomers was effective at preventing Aß42-dependent platelet aggregation. These results support a role for Aß42 oligomers in platelet hyperactivity.

dc.publisherInforma Healthcare
dc.titleOligomeric and fibrillar amyloid beta 42 induce platelet aggregation partially through GPVI
dc.typeJournal Article
curtin.accessStatusFulltext not available
curtin.facultyFaculty of Health Sciences

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record